We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association of endostatin with mortality in patients with chronic heart failure.
- Authors
Gouya, Ghazaleh; Siller‐Matula, Jolanta M.; Fritzer‐Szekeres, Monika; Neuhold, Stephanie; Storka, Angela; Neuhofer, Lisa M.; Clodi, Martin; Hülsmann, Martin; Pacher, Richard; Wolzt, Michael
- Abstract
Background Experimental data imply that in decompensated heart failure ( HF), the anti-angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all-cause mortality in a prospective cohort study of chronic HF patients. Methods In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow-up of 31 months. Results One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all-cause mortality [ HR 8·7 (95% CI 2·5-30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT-pro BNP were above the calculated cut-off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [ HR 40·8 (95% CI 4·7-354·6); P = 0·001] compared with values lower than the cut-offs. Conclusions Serum endostatin concentrations are independently associated with all-cause mortality. Furthermore, combination of endostatin and NT-pro BNP discriminates patients at high risk.
- Subjects
ENDOSTATIN; HEART failure; NEOVASCULARIZATION inhibitors; MULTIVARIATE analysis; BIOMARKERS; COHORT analysis
- Publication
European Journal of Clinical Investigation, 2014, Vol 44, Issue 2, p125
- ISSN
0014-2972
- Publication type
Article
- DOI
10.1111/eci.12197